SeedCue

News

Read the latest news!
Gallery inside!

T-Therapeutics, a biotechnology company developing next-generation T cell receptor (TCR) therapeutics for cancer and autoimmune disease, announced the successful expansion of its Series A financing, raising an additional $32 million.

Gallery inside!

Unconventional Ventures announced he the first close of Fund II, an €80 million fund dedicated to backing scalable, sustainable companies founded by diverse and underrepresented teams.

Authors

Oana Modorcea
Founder & Managing Editor